ArticleThe Journal of biological chemistry2011
Exogenous ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine expression.
Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- Role of Ceramide Kinase/C1P in the Regulation of Cell Growth and Survival.International journal of molecular sciences · 2025Review
- Macrophage involvement in idiopathic inflammatory myopathy: pathogenic mechanisms and therapeutic prospects.Journal of inflammation (London, England) · 2024Review
- Functional Insights into the Sphingolipids C1P, S1P, and SPC in Human Fibroblast-like Synoviocytes by Proteomic Analysis.International journal of molecular sciences · 2024Article
- Anti-Obesity Activity ofNutrients · 2024Article
- Acid ceramidase regulates innate immune memory.Cell reports · 2023Article
- The synthetic phospholipid C8-C1P determines pro-angiogenic and pro-reparative features in human macrophages restraining the proinflammatory M1-like phenotype.Frontiers in immunology · 2023Article
- Changes in PCSK 9 and apolipoprotein B100 in Niemann-Pick disease after enzyme replacement therapy with olipudase alfa.Orphanet journal of rare diseases · 2021Article
- Distinctive sphingolipid patterns in chronic multiple sclerosis lesions.Journal of lipid research · 2020Article
- Article
- Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.Journal of lipid research · 2019Review
- Glucosylceramidase Maintains Influenza Virus Infection by Regulating Endocytosis.Journal of virology · 2019Article
- Role of Bioactive Sphingolipids in Inflammation and Eye Diseases.Advances in experimental medicine and biology · 2019Article
- Crosslink between lipids and acute uveitis: a lipidomic analysis.International journal of ophthalmology · 2018Article
- Bioactive Lipids and Chronic Inflammation: Managing the Fire Within.Frontiers in immunology · 2018Review
- Translational Aspects of Sphingolipid Metabolism in Renal Disorders.International journal of molecular sciences · 2017Review
- Article
- The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate in Inflammation and Cancer.Mediators of inflammation · 2017Review
- C1P Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Preventing NF-κB Activation in Neutrophils.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Exogenous ceramide-1-phosphate (C1P) and phospho-ceramide analogue-1 (PCERA-1) regulate key macrophage activities via distinct receptors.Immunology letters · 2016Article
- Sphingolipids in spinal cord injury.International journal of physiology, pathophysiology and pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Toll-like receptor 4 (TLR4) is a component of the innate immune system that recognizes a diverse group of molecular structures, such as lipopolysaccharide (LPS) from Gram-negative bacteria. TLR4 signaling ultimately leads to activation of the transcription factor, nuclear factor κB (NF-κB), and the production of cytokines. Ceramide is a bioactive sphingolipid that has been suggested to regulate TLR4-induced NF-κB signaling, although reports on the role of ceramide in TLR4 activation conflict. We investigated the possibility that ceramide metabolites, such as ceramide-1-phosphate (C-1-P), may explain these discrepancies. We now report that exogenous C-1-P, but not ceramide, reduces NF-κB-mediated gene transcription in HEK 293 cells stably transfected with human TLR4, CD14, and MD-2. We demonstrate that inhibition of NF-κB by exogenous C-1-P is dose-dependent and specific to TLR4 in a reporter assay. We further demonstrate a requirement for both the phosphate moiety and the sphingoid backbone to inhibit LPS-activated NF-κB transcription. Specifically, C-1-P prevents the degradation of IκB, the phosphorylation of the p65 subunit of NF-κB, and LPS-stimulated MAPK activation. The functional consequence of C-1-P inhibition of NF-κB is a reduction in LPS-mediated cytokine release from HEK 293 TLR4-expressing cells and human peripheral blood mononuclear cells. Taken together, these data demonstrate that C-1-P may function as an anti-inflammatory lipid mediator of immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.